NCT07169409 Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
| NCT ID | NCT07169409 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Boulder Care |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-06-10 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 250 participants in total. It began in 2025-06-10 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Our primary objective is to evaluate the ability of Boulder Care's telehealth-platform to create the necessary paradigmatic shift in Opioid Use Disorder (OUD) treatment to reach vulnerable populations, with targets that support both equitable and culturally-specific OUD treatment as well as business profitability.
Eligibility Criteria
Inclusion Criteria: * History of Opioid Use Disorder (OUD) * Starting OUD treatment with buprenorphine, or within 45 days of starting or restarting this medication * Speak and understand English Exclusion Criteria: * History of allergic reaction to buprenorphine * Plans to move out of a Boulder Care-affiliated state site in the next 12 months (precluding continuation of care) * Untreated mental or medical health conditions that, in the opinion of the participant, would preclude study participation
Contact & Investigator
Andrea Baron, MPH
STUDY DIRECTOR
Boulder Care
Frequently Asked Questions
Who can join the NCT07169409 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07169409 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07169409 currently recruiting?
Yes, NCT07169409 is actively recruiting participants. Contact the research team at andrea.baron@boulder.care for enrollment information.
Where is the NCT07169409 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT07169409 clinical trial?
NCT07169409 is sponsored by Boulder Care. The principal investigator is Andrea Baron, MPH at Boulder Care. The trial plans to enroll 250 participants.